## BRO: Brown & Brown, Inc. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_20 -4.7% below STRENGTH zone (4.0-10.0%); PEG 4.41 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.16)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Brant Point Investment Management LLC Makes New $3.33 Million Investment in Brown & Brown, Inc. $BRO**
- Source: MarketBeat | 20251208T100754 | Somewhat-Bullish | Relevance: 100%
-  Brant Point Investment Management LLC has made a new $3.33 million investment in Brown & Brown, Inc. (NYSE:BRO) by purchasing 30,000 shares in the second quarter. Other institutional investors like Vanguard Group Inc. and Norges Bank also significantly increased their holdings in the financial services provider. The company recently increased its quarterly dividend to $0.165, and analysts currently rate the stock as "Hold" with an average price target of $102.69.

**2. Is Brown & Brown Stock Underperforming the S&P 500?**
- Source: Markets Financial Content | 20251209T140753 | Neutral | Relevance: 99%
- Brown & Brown, Inc. (BRO) stock has significantly underperformed the S&P 500, with declines of 18.6% over three months, 29.8% over six months, and 28.9% over the past year. This underperformance is attributed to margin pressure and slower organic growth, despite the company exceeding Q3 revenue and EPS forecasts. Wall Street analysts currently hold a "Hold" rating on BRO, with a price target suggesting a potential 25.5% upside.

**3. Brown & Brown Releases 2026 Employer Health and Benefits Strategy Survey: Cost Control Takes Center Stage**
- Source: Business Wire | 20251208T140817 | Somewhat-Bullish | Relevance: 99%
- Brown & Brown's 2026 Employer Health and Benefits Strategy Survey indicates a shift in employer priorities, with cost control now topping the list due to escalating medical and pharmacy expenses. Despite this focus, employers remain committed to employee well-being, increasing budgets for programs and enhancing parental leave. The survey also highlights the ongoing challenge of balancing access and cost for GLP-1 drugs for weight loss.

**4. 44,775 Shares in Brown & Brown, Inc. $BRO Acquired by iSAM Funds UK Ltd**
- Source: MarketBeat | 20251209T140753 | Somewhat-Bullish | Relevance: 99%
-  iSAM Funds UK Ltd disclosed in its latest 13F filing that it acquired 44,775 shares of Brown & Brown, Inc. (NYSE:BRO), valued at approximately $4.96 million. This investment makes Brown & Brown the largest holding in iSAM Funds UK Ltd's portfolio, representing about 1.1% of its total assets. The financial services provider recently reported strong quarterly earnings, exceeding analyst expectations, and increased its quarterly dividend.

**5. Brown & Brown, Inc.'s (NYSE:BRO) Popularity With Investors Is Under Threat From Overpricing**
- Source: 富途牛牛 | 20251207T140827 | Neutral | Relevance: 98%
- Brown & Brown, Inc. (NYSE:BRO) may be overvalued currently, with its shares trading at 30.6x earnings, above the industry average of 14.8x. This high valuation could deter new investors, especially given the company's growth rate is projected to slow. While a potential dividend increase or share buyback could boost investor sentiment, the current overpricing poses a risk to its future popularity.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $84 | $102 | -18% |
| 2025-11-17 | Morgan Stanley | $85 | $95 | -11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Equal-Weight |
| 2025-11-17 | Morgan Stanley | main | Equal-Weight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 10.9% (+4.8%)
- Blackrock Inc.: 6.1% (+2.2%)
- Capital World Invest: 5.1% (+81.1%)
- Principal Financial : 4.5% (+13.4%)
- State Street Corpora: 3.8% (+5.3%)

### Key Risks

1. Valuation stretched: PEG 4.4x requires aggressive growth execution.
2. Long-term trend broken: trading 23.7% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.41 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 19%). Revenue growth strong at 23% YoY. Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.5B |
| Beta | 0.81 |
| 52W Range | $76.17 - $125.68 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.41 |
| Forward P/E | 16.6 |
| Current P/E | 18.2 |
| YoY Growth | 9.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.4% to -4.7% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.7pp (needs >4.0% for momentum thesis). Underperforming sector by 4.2pp, stock-specific weakness. Below SMA200 (0.76x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.69% (CS: 17) | Weak |
| RSI_14 | 34.0 | Neutral |
| MACD Histogram | 0.19 | Bullish |
| vs SMA20 | 0.973x | Below |
| vs SMA50 | 0.915x | Below |
| vs SMA200 | 0.763x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.64
- **Stop Loss:** $74.16 (4.5% risk)
- **Target:** $81.12 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 287
- **Position Value:** $22,282.68
- **Portfolio %:** 22.28%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

### Earnings

**Next:** 2026-01-26 (Est: $0.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.93 | $1.05 | +12.9% |
| 2025Q2 | $0.99 | $1.03 | +4.6% |
| 2025Q1 | $1.30 | $1.29 | -0.5% |
| 2024Q4 | $0.77 | $0.86 | +12.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*